CN117815452A - Artificial blood vessel medicine carrying method and artificial blood vessel - Google Patents
Artificial blood vessel medicine carrying method and artificial blood vessel Download PDFInfo
- Publication number
- CN117815452A CN117815452A CN202410018978.4A CN202410018978A CN117815452A CN 117815452 A CN117815452 A CN 117815452A CN 202410018978 A CN202410018978 A CN 202410018978A CN 117815452 A CN117815452 A CN 117815452A
- Authority
- CN
- China
- Prior art keywords
- artificial blood
- blood vessel
- drug
- carrying
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 105
- 239000002473 artificial blood Substances 0.000 title claims abstract description 98
- 239000003814 drug Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 229940079593 drug Drugs 0.000 claims abstract description 50
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 40
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 40
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 40
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000012620 biological material Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 11
- 241000282414 Homo sapiens Species 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 44
- 241000283690 Bos taurus Species 0.000 claims description 26
- 210000003516 pericardium Anatomy 0.000 claims description 26
- 238000011068 loading method Methods 0.000 claims description 21
- 238000002513 implantation Methods 0.000 claims description 16
- 238000007654 immersion Methods 0.000 claims description 8
- 238000012377 drug delivery Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- 238000009958 sewing Methods 0.000 claims description 3
- 238000004804 winding Methods 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 238000002791 soaking Methods 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 description 23
- 238000003756 stirring Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000009966 trimming Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a drug-carrying method of an artificial blood vessel and the artificial blood vessel, wherein the whole or the end part of the artificial blood vessel prepared from a biological material is immersed into a drug-carrying composition for carrying drug, the biological material is a human or animal source material, and the drug-carrying composition is a solution containing paclitaxel. In the invention, the dimethyl sulfoxide solution containing taxol is used as the medicine carrying composition, and when the medicine carrying treatment is carried out on the artificial blood vessel prepared by the biological material, the artificial blood vessel can obtain good medicine carrying effect only by soaking the artificial blood vessel in the medicine carrying composition, so that the method is simple and convenient to operate, and can be widely applied to the on-site medicine carrying treatment of the artificial blood vessel prepared by the biological material in practical application.
Description
Technical Field
The invention relates to the technical field of biomedical treatment, in particular to an artificial blood vessel drug loading method and an artificial blood vessel.
Background
Currently, vascular prostheses are used in a large number of clinics and have achieved good results in some aspects. In the application of artificial blood vessels, the problem that the blood vessels become narrow or blocked due to proliferation in the blood vessels after implantation often exists, and the functions of the blood vessels are affected. Thus, how to reduce the proliferation in blood vessels is one of the main problems faced by artificial blood vessels in applications.
To inhibit vascular proliferation, one current solution is to use drug loading on an artificial blood vessel, such as forming a drug-loaded coating on the vessel wall; however, this method is only suitable for vascular prostheses made of polymer materials, and for vascular prostheses made of biological materials, the drug loading effect of the existing drug loading method is often poor, so that the clinical application of the existing drug loading method is limited.
Disclosure of Invention
The invention aims to provide an artificial blood vessel drug loading method and an artificial blood vessel, which are used for solving the problem that the artificial blood vessel prepared by adopting biological materials has poor drug loading effect in application.
The invention is realized by the following technical scheme:
the artificial blood vessel drug carrying method comprises the steps of immersing the whole or the end part of an artificial blood vessel prepared from biological materials into a drug carrying composition for drug carrying treatment, wherein the biological materials are human-derived or animal-derived materials; the drug-carrying composition is a solution containing paclitaxel.
The solvent adopted by the drug-carrying composition is one or more of dimethyl sulfoxide, N-methyl pyrrolidone and N, N-dimethylacetamide.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 0.1-100mg/ml.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 0.5-10mg/ml.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 1-3mg/ml.
In some embodiments, the vascular prosthesis has an immersion time in the drug-loaded composition of not less than 10 s.
In some embodiments, where the drug-loaded treatment is performed by immersing the vascular prosthesis tip in a drug-loaded composition, the vascular prosthesis tip is immersed in a length of 0.2-25cm.
In some embodiments, where the drug-loaded treatment is performed by immersing the vascular prosthesis tip in a drug-loaded composition, the vascular prosthesis tip is immersed in a length of 0.2-2cm.
In some embodiments, the vascular prosthesis is sewn with bovine pericardium windings.
In some embodiments, the bovine pericardium has a thickness of 0.2-0.9mm.
In some embodiments, the bovine pericardium is an anticalcification treated bovine pericardium.
In some embodiments, the resulting vascular prosthesis is sterilized and then packaged, the vascular prosthesis is removed and trimmed to the desired length, port shape prior to implantation of the vascular prosthesis, and the vascular prosthesis is then subjected to a drug loading process in a drug loading composition.
In some embodiments, the drug-loaded treated vascular prosthesis is soaked in sterile saline for 0.5-30min.
On the other hand, the invention also provides an artificial blood vessel obtained by adopting the artificial blood vessel drug delivery method.
Compared with the prior art, the invention has the following advantages:
in the invention, the dimethyl sulfoxide solution containing taxol is used as the medicine carrying composition, and when the medicine carrying treatment is carried out on the artificial blood vessel prepared by the biological material, the artificial blood vessel can obtain good medicine carrying effect only by soaking the artificial blood vessel in the medicine carrying composition, so that the method is simple and convenient to operate, and can be widely applied to the on-site medicine carrying treatment of the artificial blood vessel prepared by the biological material. The drug-carrying composition may also employ a solvent similar to dimethylsulfoxide, such as N-methylpyrrolidone, N-dimethylacetamide and the like, or a mixture of the above.
In the drug-carrying composition, the dimethyl sulfoxide and other similar solvents can better dissolve the taxol, and when the artificial blood vessel of the biological material is soaked in the drug-carrying composition solution, the solution can well diffuse into the biological material and form good distribution in the biological material so as to achieve better drug-carrying effect; in the practical application process of the artificial blood vessel, when the artificial blood vessel of the biological material is put into the environment with water again, such as normal saline, because the taxol is insoluble in the water, the taxol can be rapidly precipitated in the biological material and adsorbed in tissue fibers in the biological material, and after the artificial blood vessel of the biological material is implanted, the taxol can be slowly released from the biological material, thereby playing the effect of reducing the hyperplasia in the blood vessel, and well solving the problems of the artificial blood vessel of the biological material in practical application.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following description will briefly describe the drawings in the embodiments, it being understood that the following drawings only illustrate some embodiments of the present invention and should not be considered as limiting the scope, and that other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic structural diagram of an embodiment of an artificial blood vessel according to the present invention.
Wherein:
10. artificial blood vessel, 20, suture.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention.
The artificial blood vessel adopting biological materials is derived from natural growth tissues of human beings or animals, and is usually required to be soaked in a liquid environment simulating body fluid for preservation, and the material is rich in water due to the fact that the liquid environment is rich in water, so that medicine carrying effects are poor when a conventional medicine carrying mode is adopted for carrying medicine.
Aiming at the problems, a great deal of researches show that when biological materials are immersed into dimethyl sulfoxide solution containing taxol for carrying medicine, a good medicine carrying effect can be achieved, and the problems existing in the medicine carrying treatment of artificial blood vessels of biological materials and the practical application of the artificial blood vessels at present are well solved.
In some embodiments of the present invention, the method for loading the artificial blood vessel is that the whole or the end part of the artificial blood vessel prepared by biological materials is immersed into a drug loading composition for drug loading treatment, wherein the biological materials are human or animal source materials, such as blood vessels, pericardium and the like; the drug-carrying composition used for drug-carrying treatment is a solution containing paclitaxel, such as dimethyl sulfoxide solution containing paclitaxel with dimethyl sulfoxide as solvent.
The drug-carrying composition herein may also employ a solvent similar to dimethylsulfoxide, such as N-methylpyrrolidone, N-dimethylacetamide and the like, or a mixture of the above components.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 0.1-100mg/ml.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 0.5-10mg/ml.
In some embodiments, the concentration of paclitaxel in the drug-loaded composition is 1-3mg/ml.
Based on the technical idea of the invention and the effect of the drug-carrying composition in carrying out drug-carrying treatment on the artificial blood vessel, it is easy to think that the drug-carrying composition and the drug-carrying method can be also applied to the drug-carrying treatment of other artificial prostheses prepared by adopting biological materials.
In some embodiments, the artificial blood vessel has an immersion time in the drug-loaded composition of not less than 10 s at the time of drug-loaded treatment. Generally, according to the differences of materials, specifications and the like adopted by the artificial blood vessel and the concentration of paclitaxel in the drug-carrying composition, the immersion time of drug-carrying treatment can be 0.5-20min, and the drug-carrying composition solution can be stirred during the immersion of the drug-carrying treatment.
In some embodiments, the entire vascular prosthesis of the biological material may be immersed in the drug-loaded composition for drug-loading treatment.
After the whole artificial blood vessel is carried in the drug carrying composition solution, the surface drying treatment can be carried out by adopting the dry film technology to separate the whole artificial blood vessel from the liquid environment, and then the product is packaged after the sterilization treatment, so that the sterile product of the artificial blood vessel can be prepared. The sterilization treatment can be carried out by conventional sterilization methods such as irradiation sterilization, ethylene oxide sterilization, and chemical liquid sterilization.
In some embodiments, only two ends of the vascular prosthesis of the biological material may be immersed in the drug-carrying composition for drug-carrying treatment, where the length of immersion of the ends of the vascular prosthesis may be selected to be 0.2-25cm, or 0.2-2cm, as desired. When the end part of the artificial blood vessel is immersed and carried with medicine, physiological saline can be used for treating the part of the artificial blood vessel which is not immersed, so that the artificial blood vessel is kept moist, and dehydration denaturation is avoided; for the dry vascular prosthesis, the above-described procedure may not be used in the drug delivery process.
In some embodiments, vascular prosthesis 10 may be produced by winding bovine pericardium into a tube and then sewing with suture 20, as shown in FIG. 1.
In some embodiments, the bovine pericardium thickness may be selected to be 0.2-0.9mm, or 0.4-0.8mm as desired.
In some embodiments, the bovine pericardium is an anticalcification treated bovine pericardium. The anti-calcification treatment of bovine pericardium can be one or more of decellularization treatment (such as surfactant washing, freeze thawing, etc.) for removing cell debris and phospholipid in bovine pericardium, or treatment for blocking free aldehyde groups introduced by glutaraldehyde crosslinking fixation in bovine pericardium by chemical reaction.
In some embodiments, the vascular prosthesis produced by sewing or other means may be used for aseptic processing and stored in a sterile barrier package; prior to implantation of the prosthesis, the prosthesis is removed from the sterile package, trimmed to the length required for implantation and trimmed to the end to the desired port shape using sterile scissors, and then the prosthesis is placed into a drug-loaded composition for drug-loading treatment.
In some embodiments, the drug-loaded vascular prosthesis may be prepared for implantation by immersing the drug-loaded vascular prosthesis in sterile saline for 0.5-30min.
In another aspect, some embodiments further relate to an artificial blood vessel prepared by the artificial blood vessel drug loading method.
The method for carrying out drug delivery treatment on an artificial blood vessel according to the present invention will be specifically described with reference to the following examples.
Example 1
Preparing dimethyl sulfoxide solution containing paclitaxel with concentration of 0.5mg/ml;
immersing the whole artificial blood vessel prepared by adopting bovine pericardium material into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, and then taking out the artificial blood vessel for implantation.
Example 2
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 1mg/ml;
immersing the whole artificial blood vessel prepared by adopting bovine pericardium material into the drug-carrying composition solution, immersing for 20min, stirring the composition solution during immersing, and then taking out the artificial blood vessel for implantation.
Example 3
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
immersing the whole artificial blood vessel prepared by adopting bovine pericardium material into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, and then taking out the artificial blood vessel for implantation.
Example 4
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 10mg/ml;
immersing the whole artificial blood vessel prepared by adopting bovine pericardium material into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, and then taking out the artificial blood vessel for implantation.
Example 5
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
the whole artificial blood vessel prepared by adopting the jugular vein of the cattle is immersed into the drug-carrying composition solution, the immersing treatment is carried out for 10min, the composition solution is stirred during the immersing, and then the artificial blood vessel is taken out for implantation.
Example 6
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
immersing the end of the artificial blood vessel prepared by adopting bovine pericardium material into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, and then taking out the artificial blood vessel for implantation.
Example 7
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
the artificial blood vessel sewn by the bovine pericardium is taken out of the sterile package and trimmed to the required length, the whole body of the artificial blood vessel is immersed into the drug-carrying composition solution for 10min, the composition solution is stirred during immersion, and then the artificial blood vessel is taken out and then immersed into normal saline for implantation.
Example 8
Preparing dimethyl sulfoxide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
and taking out the artificial blood vessel sewn by adopting the bovine pericardium from the aseptic package, trimming the two ends to the required port shape, immersing the two ends of the artificial blood vessel into the drug-carrying composition solution for 10min, stirring the composition solution during immersion, taking out the artificial blood vessel, and immersing the artificial blood vessel in normal saline for implantation.
Example 9
Preparing N-methyl pyrrolidone solution containing taxol, wherein the concentration of taxol is 3mg/ml;
and taking out the artificial blood vessel sewn by adopting the bovine pericardium from the aseptic package, trimming the two ends to the required port shape, immersing the two ends of the artificial blood vessel into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, taking out the artificial blood vessel, and immersing the artificial blood vessel in normal saline for implantation.
Example 10
Preparing N, N-dimethylacetamide solution containing taxol, wherein the concentration of taxol is 3mg/ml;
and taking out the artificial blood vessel sewn by adopting the bovine pericardium from the aseptic package, trimming the two ends to the required port shape, immersing the two ends of the artificial blood vessel into the drug-carrying composition solution, immersing for 10min, stirring the composition solution during immersing, taking out the artificial blood vessel, and immersing the artificial blood vessel in normal saline for implantation.
Through the detection of the drug carrying effect of the artificial blood vessel obtained by drug carrying treatment, the artificial blood vessel prepared in the embodiment can achieve better drug carrying effect, and the drug carrying amount can meet the use requirement of reducing the hyperplasia in the blood vessel after the artificial blood vessel is implanted, so that the drug carrying composition and the drug carrying method can be well suitable for the drug carrying operation of the artificial blood vessel prepared by adopting biological materials such as bovine pericardium and the like.
In the description of the present invention, it should be noted that, as the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., are used to indicate orientations or positional relationships based on those shown in the drawings, or those that are conventionally put in use in the product of the present invention, they are merely used to facilitate description of the present invention and simplify description, and do not indicate or imply that the apparatus or elements referred to must have a specific orientation, be configured and operated in a specific orientation, and thus should not be construed as limiting the present invention.
Furthermore, the terms "horizontal," "vertical," and the like in the description of the present invention, if any, do not denote absolute levels or overhangs, but rather may be slightly inclined. As "horizontal" merely means that its direction is more horizontal than "vertical", and does not mean that the structure must be perfectly horizontal, but may be slightly inclined.
In the description of the present invention, it should also be noted that, unless explicitly stated and limited otherwise, the terms "disposed," "mounted," "connected," and "connected" should be construed broadly, and may be, for example, fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; can be directly connected or indirectly connected through an intermediate medium, and can be communication between two elements. The specific meaning of the above terms in the present invention will be understood in specific cases by those of ordinary skill in the art.
The foregoing description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, and any simple modification, equivalent variation, etc. of the above embodiment according to the technical matter of the present invention fall within the scope of the present invention.
Claims (13)
1. The artificial blood vessel drug carrying method is characterized in that the whole or the end part of an artificial blood vessel prepared from biological materials is immersed into a drug carrying composition for drug carrying treatment, and the biological materials are human-derived or animal-derived materials; the drug-carrying composition is a solution containing paclitaxel.
2. The method according to claim 1, wherein the solvent used in the drug-loading composition is one or more of dimethyl sulfoxide, N-methylpyrrolidone, and N, N-dimethylacetamide.
3. The method of claim 1 or 2, wherein the concentration of paclitaxel in the drug-loaded composition is 0.1-100mg/ml.
4. The method of claim 3, wherein the concentration of paclitaxel in the drug delivery composition is 0.5-10mg/ml.
5. The method of claim 1 or 2, wherein the artificial blood vessel has an immersion time in the drug delivery composition of not less than 10 s.
6. The method according to claim 1 or 2, wherein when the artificial blood vessel end is immersed in the drug-carrying composition for drug-carrying treatment, the immersed length of the artificial blood vessel end is 0.2 to 25cm.
7. The method according to claim 6, wherein when the artificial blood vessel end is immersed in the drug-carrying composition for drug-carrying treatment, the immersed length of the artificial blood vessel end is 0.2 cm to 2cm.
8. The method for loading a drug into an artificial blood vessel according to claim 1 or 2, wherein the artificial blood vessel is formed by winding and sewing bovine pericardium.
9. The method of claim 8, wherein the bovine pericardium has a thickness of 0.2-0.9mm.
10. The method of claim 8, wherein the bovine pericardium is an anticalcified bovine pericardium.
11. The method of claim 1 or 2, wherein the prepared artificial blood vessel is packaged after aseptic treatment, the artificial blood vessel is taken out and trimmed to a required length and port shape before implantation, and then the artificial blood vessel is subjected to drug loading treatment in a drug loading composition.
12. The method for loading artificial blood vessels according to claim 11, wherein the artificial blood vessels after the loading treatment are soaked in sterile physiological saline for 0.5-30min.
13. An artificial blood vessel obtained by the artificial blood vessel drug delivery method according to any one of claims 1 to 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410018978.4A CN117815452A (en) | 2024-01-05 | 2024-01-05 | Artificial blood vessel medicine carrying method and artificial blood vessel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410018978.4A CN117815452A (en) | 2024-01-05 | 2024-01-05 | Artificial blood vessel medicine carrying method and artificial blood vessel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117815452A true CN117815452A (en) | 2024-04-05 |
Family
ID=90517172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410018978.4A Pending CN117815452A (en) | 2024-01-05 | 2024-01-05 | Artificial blood vessel medicine carrying method and artificial blood vessel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117815452A (en) |
-
2024
- 2024-01-05 CN CN202410018978.4A patent/CN117815452A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3797673B2 (en) | Method for treating implantable biological tissue to reduce calcification and bioprosthesis treated in such a manner | |
| US10390946B2 (en) | Method for the preparation of biological tissue for dry use in an implant | |
| CA2179017C (en) | Peracetic acid sterilization | |
| AU756173B2 (en) | Method for tissue fixation | |
| DE69909096T2 (en) | NETWORKING OF BIOPROTHESIS MATERIAL TO REDUCE CALCIFICATION AFTER IMPLANTATION | |
| US6969523B1 (en) | Collagen/glycosaminoglycan matrix stable to sterilizing by electron beam radiation | |
| RU2432968C2 (en) | Artificial biological implant for nerve guide membrane and method of its manufacturing | |
| US10722613B2 (en) | Method of preparing calcification-resistant bioprosthetic tissue | |
| BRPI0306744B1 (en) | method to mitigate post-implantation calcification of a bioprosthetic material | |
| US8137411B2 (en) | Thin collagen tissue for medical device applications | |
| EP0160025A1 (en) | Biomaterial. | |
| WO2018167536A1 (en) | Implantable material and method for preserving | |
| JP2010213984A (en) | In-vivo implanting medical material containing softener and/or moisturizer, method of adjusting content of softener and/or moisturizer in in-vivo implanting medical material, and method for producing in-vivo implanting medical material | |
| KR20210124886A (en) | Method of preparing biological tissue for surgical implantation | |
| CN117815452A (en) | Artificial blood vessel medicine carrying method and artificial blood vessel | |
| EP4378309A1 (en) | Sterilizing biological tissue with supercritical carbon dioxide | |
| US12023416B2 (en) | Collagen fibers and articles formed therefrom | |
| WO2024114050A1 (en) | Biological tissue material, preparation method therefor, and use thereof | |
| RU2802349C1 (en) | Method of decellularization of a cardiovascular system homograft with supercritical carbon dioxide | |
| RU2008767C1 (en) | Method for conservation of biological tissues for prosthetics of heart and vessel valves | |
| WO2011115612A1 (en) | Thin collagen tissue for medical device applications | |
| US20200171205A1 (en) | Collagen fibers and articles formed therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |